Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3569228 | 0.82 | — | — | |
| SCHEMBL689988 | 0.81 | — | — | |
| Benzamide SCHEMBL28297315 | 0.81 | POLB (0.42) | CRBN | |
| SCHEMBL33371399 | 0.81 | CRBN (0.33) | CRBN | |
| SCHEMBL68773 | 0.81 | CRBN (0.33) | CRBN | |
| SCHEMBL1816977 | 0.81 | — | — | |
| SCHEMBL6196078 | 0.78 | CRBN (0.35) | CRBN | |
| SCHEMBL1600759 | 0.77 | CRBN (0.30) | CRBN | |
| SCHEMBL2138420 | 0.77 | CRBN (0.34) | CRBN | |
| SCHEMBL10555085 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707774-A | Bromination method of microwave-assisted 1,5,6, 7-tetrahydro-4H-indol-4-one derivative | 浙江工业大学 | 2025-03-28 | — | — | CN | claimed |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | claimed |
| EP-4304720-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| WO-2022192745-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-09-15 | — | — | WO | claimed |
| US-8329683-B2 | Treatment of neurofibromatosis with radicicol and its derivatives | NEXGENIX PHARMACEUTICALS, LLC (US) | 2012-12-11 | — | — | US | claimed |
| US-8063233-B2 | Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives | SPECTRUM PHARMACEUTICALS INC. (US) | 2011-11-22 | — | — | US | claimed |
| CN-101481353-B | Tetrahydro indazolone or tetrahydro indolone substituted indazole derivative and salt thereof | TONDE PHARMACEUTICAL CO LTD | 2011-07-20 | — | — | CN | claimed |
| EP-1812388-B1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS EHF (IS) | 2011-02-23 | — | — | EP | claimed |
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | NEXGENIX PHARMACEUTICALS HOLDINGS, INC. | 2010-11-18 | — | — | US | claimed |
| EP-1383742-B1 | SYNTHESIS AND METHODS OF USE OF TETRAHYDROINDOLONE ANALOGUES AND DERIVATIVES | SPECTRUM PHARMACEUTICALS INC (US) | 2010-10-27 | — | — | EP | claimed |
| US-20020061899-A1 | Methods for treatment of drug-induced peripheral neuropathy and related conditions | SPECTRUM PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | claimed |
| US-20020055506-A1 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | SPECTRUM PHARMACEUTICALS, INC. | 2002-05-09 | — | — | US | claimed |
| US-20020040031-A1 | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system | NEO THERAPEUTICS, INC. | 2002-04-04 | — | — | US | claimed |
| US-20020040032-A1 | Methods for stimulation of synthesis of synaptophysin in the central nervous system | NEOTHERAPEUTICS, INC. | 2002-04-04 | — | — | US | claimed |
| WO-2002004451-A2 | METHODS FOR STIMULATION OF SYNTHESIS OF SYNAPTOPHYSIN IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004449-A2 | METHODS FOR TREATMENT OF CONDITIONS AFFECTED BY ACTIVITY OF MULTIDRUG TRANSPORTERS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004452-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004450-A2 | METHODS FOR PREVENTION OF ACCUMULATION OF AMYLOID BETA PEPTIDE IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004448-A2 | METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| EP-0327986-A2 | Medicaments containing lactams, substituted lactams and process for their preparation | Roche Diagnostics GmbH (DE) | 1989-08-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061899-A1 | Methods for treatment of drug-induced peripheral neuropathy and related conditions | TYMP, TYMS, NGF | CRBN 1910/4885MAP3K14 1507/4885 |
| US-20020055506-A1 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | NGF, NUDT1, HPRT1 | CRBN 4281/4885MAP3K14 684/4885 |
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | HSP90AB2P, HSP90AA1, HSPA2 | CRBN 1730/4885MAP3K14 2639/4885 |
| US-20020040032-A1 | Methods for stimulation of synthesis of synaptophysin in the central nervous system | GAP43, BDNF, APP | CRBN 2515/4885MAP3K14 1947/4885 |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT1, PRMT5, PRMT6 | CRBN 1581/4885MAP3K14 2456/4885 |
| US-20020040031-A1 | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system | APP, BACE1, SARNP | CRBN 2014/4885MAP3K14 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.